Complete resection of thoracic growing teratoma syndrome (TGTS) is associated with good overall survival, although early detection and the clinician’s knowledge of systemic treatment options remain important factors, according to a study.
In this retrospective analysis, 29 patients who received surgery for TGTS were between 1999 and 2016, were included.
All patients in this study were treated with cisplatin-based chemotherapy. The median tumor size was 64.5 mm (range 10 mm -210 mm) and 10 patients had multilocalized TGTS. Complete resection was achieved in all cases.
The minor morbidity rate was 3.4%, the major morbidity rate was 6.9%, and the mortality rate was 0%.
In a long-term follow-up analysis of 28 patients with a median follow-up of 94 months (13-237 months), the 5-, 10-, and 15-year survival rates were 93%, 93%, and 84%, respectively.
Sponholz S, Chalepaki Ntelli K, Karaindros G, et al. Short-term and long-term outcomes after resection of thoracic growing teratoma syndrome. World J Urol. 2020 Oct 31. DOI: 10.1007/s00345-020-03503-6. Epub ahead of print. PMID: 33128597.